GFP/Luc Reporter Cell Line - NCI-H2228

The NCI-H2228 cell line is a highly characterized human model of non-small cell lung cancer (NSCLC), originally isolated from the pleural effusion of a patient with lung adenocarcinoma. It is exceptionally valued in thoracic oncology as a premier preclinical tool because it endogenously harbors the EML4-ALK (echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase) fusion gene, a critical oncogenic driver in a distinct subset of lung cancers. The GFP/Luc Reporter Cell Line - NCI-H2228 is an advanced, stably transfected derivative engineered to simultaneously co-express both Green Fluorescent Protein (GFP) and firefly luciferase (Luc). This robust dual-labeling construct ensures consistent, high-level expression of both functional reporter genes across sequential in vitro passages. Crucially, this stable genetic integration is achieved while rigorously preserving the fundamental biological properties, the distinct ALK-positive molecular profile, and the intrinsic tumorigenic capacity of the original parental NCI-H2228 cells.

The incorporation of this dual-reporter system significantly expands the analytical capabilities of the NCI-H2228 model for translational respiratory research. In vitro, the distinct GFP tag enables researchers to easily monitor cellular morphology, quantify proliferation rates, and isolate specific subpopulations using standard fluorescence microscopy and flow cytometry techniques. For in vivo studies, the strong luciferase expression provides the optimal foundation for non-invasive, longitudinal tracking of primary tumor progression and metastatic spread through bioluminescence imaging (BLI). Because it is a human-derived cell line, the NCI-H2228-GFP/Luc model is typically engrafted into immunocompromised mice (such as athymic nude or NSG strains) to establish reliable subcutaneous xenografts or clinically relevant orthotopic lung models. This specialized reporter line serves as an indispensable platform for evaluating the therapeutic efficacy of targeted pharmacological compounds, specifically ALK tyrosine kinase inhibitors (TKIs), and for investigating mechanisms of acquired drug resistance. By facilitating the real-time, accurate quantification of tumor burden in living subjects, it greatly accelerates preclinical discoveries in precision lung oncology.